Τίτλος:
Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Introduction: Usage of automated insulin delivery systems is increasing for the treatment of people with type 1 diabetes (T1D). This study compared long-term cost-effectiveness of the Advanced Hybrid Closed Loop MiniMed 780G (AHCL) system versus sensor augmented pump (SAP) system with predictive low glucose management (PLGM) or multiple daily injections (MDI) plus intermittently scanned continuous glucose monitoring (isCGM) in people with T1D in Greece. Methods: Analyses were performed using the IQVIA CORE Diabetes Model, with clinical input data sourced from various studies. In the AHCL versus SAP plus PLGM analysis, patients were assumed to have 7.5% baseline glycated hemoglobin (HbA1c), when comparing AHCL with MDI plus isCGM baseline HbA1c was assumed to be 7.8%. HbA1c was reduced to 7.0% following AHCL treatment initiation but remained at baseline levels in the comparator arms. Analyses were performed from a societal perspective over a lifetime time horizon. Future costs and clinical outcomes were discounted at 1.5% per annum. Results: AHCL was associated with increased quality-adjusted life expectancy of 0.284 quality-adjusted life years (QALYs) and EUR 10,173 lower mean total lifetime costs with SAP plus PLGM. Compared with MDI plus isCGM, AHCL was associated with increased quality-adjusted life expectancy of 2.708 QALYs, EUR 76,396 higher mean total lifetime costs, and an incremental cost-effectiveness ratio of EUR 29,869 per QALY. Extensive sensitivity analysis confirmed the robustness of results. Conclusions: Over patient lifetime, the MiniMed 780G system is likely to be cost saving compared with the SAP plus PLGM system and cost-effective compared with MDI plus isCGM in people with T1D in Greece. © Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.
Συγγραφείς:
Lambadiari, V.
Ozdemir Saltik, A.Z.
De Portu, S.
Buompensiere, M.I.
Kountouri, A.
Korakas, E.
Sharland, H.
Cohen, O.
Περιοδικό:
Diabetes Technology and Therapeutics
Εκδότης:
MARY ANN LIEBERT INC PUBL
Λέξεις-κλειδιά:
antidiabetic agent; glycosylated hemoglobin; human insulin; insulin, blood glucose monitoring; cost benefit analysis; glucose blood level; Greece; human; insulin dependent diabetes mellitus; insulin infusion; quality adjusted life year, Blood Glucose; Blood Glucose Self-Monitoring; Cost-Benefit Analysis; Diabetes Mellitus, Type 1; Glycated Hemoglobin A; Greece; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Insulin, Regular, Human; Quality-Adjusted Life Years
DOI:
10.1089/dia.2021.0443
